Monopar Therapeutics (MNPR) Cash from Investing Activities (2022 - 2025)

Monopar Therapeutics (MNPR) has 4 years of Cash from Investing Activities data on file, last reported at -$62.2 million in Q4 2025.

• For the quarter ending Q4 2025, Cash from Investing Activities fell 333.72% year-over-year to -$62.2 million; the trailing twelve-month figure through Dec 2025 stood at -$63.5 million (down 342.54% YoY), and the FY2025 full-year result was -$63.5 million, down 342.54% from the prior year.
• Cash from Investing Activities retreated to -$62.2 million in Q4 2025, from -$2.1 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $3.0 million in Q4 2023 to a low of -$62.2 million in Q4 2025.
• A 4-year average of -$6.0 million and a median of -$325828.0 in 2025 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities sank 582.7% in 2024 and soared 49100.99% in 2025, its largest moves.
• Tracing MNPR's Cash from Investing Activities over 4 years: stood at -$4.9 million in 2022, then surged by 160.39% to $3.0 million in 2023, then slumped by 582.7% to -$14.3 million in 2024, then plunged by 333.72% to -$62.2 million in 2025.
• Business Quant data shows MNPR's Cash from Investing Activities at -$62.2 million in Q4 2025, -$2.1 million in Q3 2025, and $1.2 million in Q2 2025.